Antibe Therapeutics Inc provides therapies for inflammation arising out of different medical conditions.
The biotechnology company specializes in producing and developing safe and non-addictive drugs for pain management and inflammation.
Through its through its hydrogen sulfide platform, the Toronto-based company develops and manufactures improved medicines, drugs, and therapies to counter the pain and inflammatory effects, including significant gastrointestinal bleeding and ulcers, that result from NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) used in various medical conditions.
The company offers non-addictive pain and inflammatory solutions through an extensive product pipeline.
Otenaproxesul, formerly ATB-346, is used for chronic pain and inflammation. The company reportedly has an Intellectual Property Right (IPR) on the drug. The product is patented and sold in the key markets across the United States, European Union, United Kingdom and Japan. The biotech firm claims that Otenaproxesul is licensed to four licensees for commercial use in 58 countries, including Knight Therapeutics, Kwandong Pharmaceutical, Laboratoire Acbel and Nuance Pharma.
It is a non-addictive analgesic to treat post-operative severe acute pain. The Canadian company claims that currently the drug is subject to Investigational New Drug enabling studies.
ATB-340 is an anti-thrombotic and anti-cancer drug that is a gastrointestinal-protective version of aspirin.
The biotechnology company is also focusing on drug solutions for Inflammatory Bowel Disease (IBD).
Through its wholly owned subsidiary, Citagenix Inc, the company engages in the marketing and distribution of regenerative drugs and medication for dental and orthopaedic purposes. In addition, Antibe Therapeutics claims to generate majority of the total revenue from this segment.
In March 2021, the therapeutics firm announced that it had reportedly received an approval for IND (Investigational New Drug) application for undertaking clinical trials for otenaproxesul by the U.S. Food and Drug Administration (FDA). The firm would initiate human clinical trials and the Phase 3 program for developing treatment for osteoarthritis pain by 2021 end reportedly.
Furthermore, according to a press release dated June 3, 2021, Antibe Therapeutics closed the amalgamation transaction with Antibe Holdings Inc to unify the Intellectual Property Rights ownership. The amalgamation transaction enabled Antibe to hold 100 per cent interest in the patent portfolio of the holding company, thus removing the royalty payment obligation in future revenues reportedly.